The triplet combination met its primary endpoint: demonstrating promising tumor microenvironment changes by significantly increasing the percentages of tumor-infiltrating activated T cells (CD3+ CD8+ CD137+ T cells) and activated, cytotoxic effector T cells (CD3+ CD8+ GZMB+ CD137+ T cells). This evidence concerns the gene TNFRSF9 and neoplasm.